Paper-based process-driven delays are no longer an issue for Ci-DMS MES customers ($300 B value lost in 2018*).
Our MES solution highlights deviations enabling batch release by exception and interfaces with the Enterprise Resource Planning (ERP) system to automatically update stock records.
*Source: various including McKinsey & Co & Pharmaceutical Engineering.
With increasing demands for higher output, and lower overheads, can you afford the costs associated with a batch failure? (typically, 47% First Pass Yield (FPY) rate (zero defects) in paper-based pharmaceutical manufacturing*)
Ci-DMS MES uses the Right FIrst TIme method, manufacturing errors/deviations are highlighted when they occur, and the batch cannot be continued until the issue is resolved, safeguarding against batch failure and increasing the FPY rate.
A global Ci-DMS MES customer saves in excess of $400K per year and avoids two potential failed batches per month in their USA plant.
*source: various including McKinsey & Co & Pharmaceutical Engineering.
Upwards of $1.77 can be added to the cost per a drug package as a result of the high levels of investment needed to comply with the Falsified Medicines Directive (FMD)*
Ci-DMS MES is configured and validated for compliance, electronic records and processes improve data integrity whilst reducing our customers’ overheads associated with maintaining compliance.
In most cases, a return on investment is achieved within one year.
*source: Capgemini Consulting
The world’s largest manufacturer of OTC & healthcare medicines has made significant savings in ensuring quality control and eliminating QC checking.
One of the world's leading research-based pharmaceutical companies has benefited from having Ci-DMS in operation and fully supported for over 7 years maintaining accurate stock control.
For many paper-based manufacturers Cost of Goods Sold (COGS) is at least 27% of sales and can be as high as 45%*.
Much of this cost is in post-batch analysis and reporting and is often an intense and demanding activity requiring highly trained people.
Ci-DMS MES extensive and real-time management reporting capabilities significantly reduce the costs of post-production analysis. Electronic records improve data integrity, reduce the risk of human error, and electronic signatures ensure FDA / EMA compliance.
*source: Various including McKinsey & Co and J Pharm Innov